New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
14:08 EDTVVUSVIVUS Qsymia Q4 patients beter but revenues below Street, says Credit Suisse
Credit Suisse said Qsymia Q4 prescription numbers are better than expected but revenues are likely to come in below consensus. The firm rates shares an Outperform with a $16 price target.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
07:03 EDTVVUSVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use